US Congress House Bill 448 (Prior Session Legislation)

---

Spectrum: Partisan Bill (Democrat 26-0)
Status: Introduced on January 10 2019 - 25% progression, died in chamber
Action: 2019-09-25 - Subcommittee Hearings Held.
Text: Latest bill text (Introduced) [PDF]

Makes a series of changes relating to the prices of prescription drugs under the Medicare prescription drug benefit and Medicare Advantage (MA) prescription drug plans (PDPs). Under current law, the Centers for Medicare & Medicaid Services (CMS) may neither negotiate the prices of covered drugs nor establish a formulary. The bill repeals these restrictions and instead specifically requires the CMS to (1) negotiate the prices of covered drugs; and (2) either establish a formulary for covered drugs, or require changes to PDP formularies that take into account CMS negotiations. If the CMS is unable to negotiate an appropriate price for a drug in accordance with certain criteria, the price must be the lowest of three specified options (e.g., the average price in other countries). The CMS must identify drugs that are subject to negotiation, with priority given to certain categories of drugs based on usage and cost. Additionally, drug manufacturers must issue rebates to the CMS for drugs dispensed to eligible low-income individuals. Subject to civil monetary penalties, a Medicare or MA PDP sponsor must report, both to drug manufacturers and to the CMS, specified information related to the determination and payment of such rebates.

Medicare Drug Price Negotiation Act

Rep. Elijah Cummings [D-MD]	Sen. Peter Welch [D-VT]	Rep. Lloyd Doggett [D-TX]	Rep. Sean Maloney [D-NY]
Rep. Mark Pocan [D-WI]	Rep. Rosa DeLauro [D-CT]	Rep. Tulsi Gabbard [D-HI]	Rep. Suzanne Bonamici [D-OR]
Rep. Ilhan Omar [D-MN]	Rep. Ro Khanna [D-CA]	Rep. Eleanor Norton [D-DC]	Rep. Pramila Jayapal [D-WA]
Rep. Janice Schakowsky [D-IL]	Rep. Brian Higgins [D-NY]	Rep. Joseph Neguse [D-CO]	Rep. Steve Cohen [D-TN]
Rep. Raja Krishnamoorthi [D-IL]	Rep. Rashida Tlaib [D-MI]	Rep. Mark DeSaulnier [D-CA]	Rep. Debra Haaland [D-NM]
Rep. Jamie Raskin [D-MD]	Rep. Raul Grijalva [D-AZ]	Rep. Debbie Wasserman Schultz [D-FL]	Rep. Peter DeFazio [D-OR]
Rep. Antonio Delgado [D-NY]	Rep. Andy Kim [D-NJ]

Date	Chamber	Action
2019-09-25	House	Subcommittee Hearings Held.
2019-01-25	House	Referred to the Subcommittee on Health.
2019-01-10	House	Referred to the Subcommittee on Health.
2019-01-10	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-01-10	House	Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2019-01-10	House	Introduced in House

SB99 (Same As) 2019-01-10 - Read twice and referred to the Committee on Finance.

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/house-bill/448/all-info
Text	https://www.congress.gov/116/bills/hr448/BILLS-116hr448ih.pdf